122 related articles for article (PubMed ID: 37726118)
1. Gene of the month: GATA3.
Qiang Z; Jubber I; Lloyd K; Cumberbatch M; Griffin J
J Clin Pathol; 2023 Dec; 76(12):793-797. PubMed ID: 37726118
[TBL] [Abstract][Full Text] [Related]
2. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
[TBL] [Abstract][Full Text] [Related]
5. The Utility of GATA3 in the Diagnosis of Urothelial Carcinomas With Variant Morphologic Patterns.
Verduin L; Mentrikoski MJ; Heitz CT; Wick MR
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):509-13. PubMed ID: 26317312
[TBL] [Abstract][Full Text] [Related]
6. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
[TBL] [Abstract][Full Text] [Related]
7. Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.
Bernardo C; Monteiro FL; Direito I; Amado F; Afreixo V; Santos LL; Helguero LA
Front Endocrinol (Lausanne); 2021; 12():684140. PubMed ID: 34690921
[TBL] [Abstract][Full Text] [Related]
8. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.
Clark BZ; Beriwal S; Dabbs DJ; Bhargava R
Am J Clin Pathol; 2014 Jul; 142(1):64-71. PubMed ID: 24926087
[TBL] [Abstract][Full Text] [Related]
9. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
10. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
[TBL] [Abstract][Full Text] [Related]
11. GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies.
Lin HY; Zeng D; Liang YK; Wei XL; Chen CF
Oncotarget; 2017 May; 8(21):34750-34761. PubMed ID: 28423734
[TBL] [Abstract][Full Text] [Related]
12. Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance.
Kong X; Wang Q; Li J; Li M; Deng F; Li C
Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35388661
[TBL] [Abstract][Full Text] [Related]
13. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
[TBL] [Abstract][Full Text] [Related]
14. GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.
Abba MC; Nunez MI; Colussi AG; Croce MV; Segal-Eiras A; Aldaz CM
Breast Cancer Res; 2006; 8(6):R64. PubMed ID: 17078870
[TBL] [Abstract][Full Text] [Related]
15. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619
[TBL] [Abstract][Full Text] [Related]
17. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
18. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
19. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
20. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.
Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA
BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
